Sign In
Buy CATB
$3.36
+0.195 (+6.16%)
At Close: May 27, 2022
SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high
Catabasis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Reviews Business Progress
08:10pm, Monday, 10'th Aug 2020
Catabasis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Reviews Business Progress
Catabasis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Reviews Business Progress
12:00am, Monday, 10'th Aug 2020
Catabasis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Reviews Business Progress
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
Questions; Confusion Regarding Military Medical System
01:23pm, Thursday, 06'th Aug 2020
Your kidneys are failing and your doctor has just deployed. Now what?
SAB Biotherapeutics Awarded $35.6M from U.S. Department of Defense for COVID-19 and Scaling Rapid Response Antibody Program
12:00am, Thursday, 06'th Aug 2020
SAB Biotherapeutics awarded $35.6M from U.S. Department of Defense for COVID-19 therapeutic and scaling Rapid Response Antibody Program.
Catabasis Pharmaceuticals to Present at Virtual 2020 Wedbush PacGrow Healthcare Conference
12:00pm, Wednesday, 05'th Aug 2020
Catabasis Pharmaceuticals to Present at Virtual 2020 Wedbush PacGrow Healthcare Conference
Study: Benefits of Omega-3 on Alzheimer's Patients Reliant on Dose | WholeFoods Magazine
02:05pm, Tuesday, 04'th Aug 2020
Sioux Falls, SD—Alzheimer’s patients may need higher omega-3 intakes to see benefits than previously thought, according to a study published in The Lancet. The study looked at 33 men and women fro
Catabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive and Drug-Resistant Tuberculosis
Catabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive and Drug-Resistant Tuberculosis
Smart Dubai partners with Dubai Health Authority to upgrade inventory app
09:08am, Tuesday, 28'th Jul 2020
The smart inventory app seeks to manage the stock of medicines in Dubai to prevent any shortages.
Catabasis Pharmaceuticals to Report Second Quarter 2020 Financial Results on Monday, August 10th
12:00pm, Monday, 27'th Jul 2020
Catabasis Pharmaceuticals to Report Second Quarter 2020 Financial Results on Monday, August 10th
Catabasis Pharmaceuticals to Report Second Quarter 2020 Financial Results on Monday, August 10th
12:00am, Monday, 27'th Jul 2020
Catabasis Pharmaceuticals to Report Second Quarter 2020 Financial Results on Monday, August 10th
The Global Marine Biotechnology Market will grow by $ 2.5 bn during 2020-2024
Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy Virtual Annual Conference
12:00pm, Wednesday, 15'th Jul 2020
Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy Virtual Annual Conference
